BiotechTube

Humanized anti-Factor Bb monoclonal antibody + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Trial Timeline

Oct 11, 2021 → May 5, 2023

NCT ID
NCT06326814

About Humanized anti-Factor Bb monoclonal antibody + Placebo

Humanized anti-Factor Bb monoclonal antibody + Placebo is a phase 1 stage product being developed by Sanofi for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT06326814. Target conditions include Paroxysmal Nocturnal Hemoglobinuria.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06326814Phase 1Completed

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
41
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
DanicopanAstraZenecaPhase 3
77
LNP023NovartisPre-clinical
23
Iptacopan (LNP023)NovartisPhase 3
77
iptacopanNovartisPhase 2
52
LNP023NovartisPhase 2
52
IptacopanNovartisPre-clinical
23
IptacopanNovartisPhase 3
77
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
77
LNP023NovartisPhase 3
77
LFG316 + LNP023NovartisPhase 2
52
IptacopanNovartisPhase 3
77
CrovalimabRochePhase 3
77
ABP 959 + EculizumabAmgenPhase 3
76
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
22
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
51

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84